Abbvie Inc.

Abbvie Biotherapeutics Inc.

Louie Naumovski

Ravi Chari

Jijie Gu

Supriya Gupta

Camellia Zamiri

Dominic J Ambrosi

Jonathan A Hickson

Yingchun Li

Susan E Lappe

Xianhua Cao

Deanna L Haasch

Kurt C Gish

Christian B Allan

Edward B Reilly

Han K Kim

Daniel E Afar

Jieyi Wang

Mark Anderson

The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Anti-cMet antibody drug conjugates and methods for their use

The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.

Anti-CS1 antibodies and antibody drug conjugates

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Growing community of inventors

Los Altos, CA, United States of America

Louie Naumovski